Avanafil
FDA-approved product (tablet, oral), marketed as Avanafil, Stendra.
- Registered studies
- 24
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Erectile dysfunction
- Impotence
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Drugs used in erectile dysfunction
- FDA pharmacologic class
- Phosphodiesterase 5 Inhibitor FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis53.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
24registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Avanafil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Daily Avanafil for Erectile Dysfunction
NCT04374994 · start 2018-09-01
Registered record
- Registry ID
- NCT04374994
- Conditions
- Erectile Dysfunction
- Interventions
- Avanafil 50 MG; Placebo oral tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2018-09-01
- Completion
- 2019-10-10
- Enrolment
- 70
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionAvanafil 50 MG; Placebo oral tabletPhasePhase 4Registry statusCompletedAvanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction
NCT03169582 · start 2016-04-01
Registered record
- Registry ID
- NCT03169582
- Conditions
- Erectile Dysfunction
- Interventions
- Avanafil; Sildenafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2016-04-01
- Completion
- 2018-06-01
- Enrolment
- 78
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionAvanafil; SildenafilPhasePhase 4Registry statusUnknownEfficacy and Tolerability Study of Avanafil in Russia
NCT02503306 · start 2015-07
Registered record
- Registry ID
- NCT02503306
- Conditions
- Sexual Function and Fertility Disorders NEC-Erectile Dysfunction
- Interventions
- AVANAFIL; placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2015-07
- Completion
- 2016-03
- Enrolment
- 189
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSexual Function and Fertility Disorders NEC-Erectile DysfunctionInterventionAVANAFIL; placeboPhasePhase 3Registry statusCompletedSafety Study Looking at the Effects of Stendra on Vision
NCT02033200 · start 2014-01
Registered record
- Registry ID
- NCT02033200
- Conditions
- Vision
- Interventions
- Stendra 200 mg; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2014-01
- Completion
- 2014-01
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVisionInterventionStendra 200 mg; PlaceboPhasePhase 4Registry statusCompletedStudy Evaluating the Effects of Avanafil on Semen Parameters
NCT01768676 · start 2012-12
Registered record
- Registry ID
- NCT01768676
- Conditions
- Erectile Dysfunction
- Interventions
- avanafil; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2012-12
- Completion
- 2014-08
- Enrolment
- 181
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionavanafil; PlaceboPhasePhase 4Registry statusCompletedResearch Evaluating a PDE5 Inhibitor for Erectile Dysfunction
NCT01698684 · start 2012-09
Registered record
- Registry ID
- NCT01698684
- Conditions
- Erectile Dysfunction
- Interventions
- Placebo; Avanafil 100 mg; Avanafil 200 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2012-09
- Completion
- 2013-04
- Enrolment
- 440
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionPlacebo; Avanafil 100 mg; Avanafil 200 mgPhasePhase 4Registry statusCompletedThis Study is to Evaluate the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction.
NCT01705197 · start 2012-02
Registered record
- Registry ID
- NCT01705197
- Conditions
- Erectile Dysfunction
- Interventions
- Avanafil 100 or 200mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-02
- Completion
- 2013-11
- Enrolment
- 195
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionAvanafil 100 or 200mgPhasePhase 3Registry statusCompletedStudy the Effect of Avanafil on the Pharmacodynamics and Pharmacokinetics of Warfarin in Healthy Male Subjects
NCT01095588 · start 2010-04
Registered record
- Registry ID
- NCT01095588
- Conditions
- Erectile Dysfunction
- Interventions
- 200 mg Avanafil; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-04
- Completion
- 2010-05
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionIntervention200 mg Avanafil; PlaceboPhasePhase 1Registry statusCompletedAssess the Effect of Food on Avanafil Pharmacokinetic (PK), to Compare 2 Oral Formulations of Avanafil,and Investigate Dose Proportionality in Healthy Male Subjects
NCT01095601 · start 2010-04
Registered record
- Registry ID
- NCT01095601
- Conditions
- Healthy
- Interventions
- Avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-04
- Completion
- 2010-05
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionAvanafilPhasePhase 1Registry statusCompletedDrug Interaction Study of Avanafil and Enalapril or Amlodipine
NCT01117038 · start 2010-04
Registered record
- Registry ID
- NCT01117038
- Conditions
- Erectile Dysfunction
- Interventions
- avanafil and enalapril; avanafil and amlodipine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-04
- Completion
- 2010-05
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionavanafil and enalapril; avanafil and amlodipinePhasePhase 1Registry statusCompletedCompare the Pharmacokinetics of Omeprazole, Rosiglitazone, and Desipramine When Administered With Avanafil in Healthy Male Subjects
NCT01415128 · start 2010-04
Registered record
- Registry ID
- NCT01415128
- Conditions
- Erectile Dysfunction
- Interventions
- Omeprazole; Rosiglitazone; Desipramine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-04
- Completion
- 2010-05
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionOmeprazole; Rosiglitazone; DesipraminePhasePhase 1Registry statusCompletedHemodynamic Study of Avanafil and Two α-Adrenergic Blockers,Doxazosin and Tamsulosin
NCT01100021 · start 2010-02
Registered record
- Registry ID
- NCT01100021
- Conditions
- Erectile Dysfunction
- Interventions
- Tamsulosin and avanafil; Doxazosin and avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-02
- Completion
- 2010-04
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionTamsulosin and avanafil; Doxazosin and avanafilPhasePhase 1Registry statusCompletedTo Compare the Pharmacokinetics of Avanafil in Subjects With Mild and Moderate Renal Impairment to Subjects With Normal Renal Function.
NCT01054261 · start 2010-01
Registered record
- Registry ID
- NCT01054261
- Conditions
- Renal
- Interventions
- avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-01
- Completion
- 2010-02
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRenalInterventionavanafilPhasePhase 1Registry statusCompletedTo Assess the Safety of Avanafil in Healthy and Hepatically Impaired Male Subjects.
NCT01054430 · start 2010-01
Registered record
- Registry ID
- NCT01054430
- Conditions
- Erectile Dysfunction
- Interventions
- avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-01
- Completion
- 2010-02
- Enrolment
- 27
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionavanafilPhasePhase 1Registry statusCompletedA Phase I Crossover Study of the Hemodynamic Interactions of Avanafil & Alcohol in Healthy Male Subjects.
NCT01054859 · start 2010-01
Registered record
- Registry ID
- NCT01054859
- Conditions
- Erectile Dysfunction
- Interventions
- avanafil; alcohol; avanafil
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-01
- Completion
- 2010-01
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionErectile DysfunctionInterventionavanafil; alcohol; avanafilPhasePhase 1Registry statusCompleted